Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| vTv Therapeutics Inc.VTVT · Entity 6614 | President & CEO | December 07, 2020 | December 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
vTv Therapeutics Inc.
Report date December 07, 2020 · Filed December 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.07 · Expires 2030-12-07 | Direct | 945,579 |
Reported balance
After 2020-12-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-07 · Grant · Acquired 400,000 · Balance 945,579 F1: The option vests in three equal annual installments beginning on December 7, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in three equal annual installments beginning on December 7, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2020 Filed Dec 9, 2020 21:16 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantEmployee stock option (right to buy) · Derivative | 400,000 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001562180-20-007125 · primarydocument.xml · derivative · entry 1 Holcombe Stephen L. · CIK 0001648953 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945,579 Underlying: Class A Common Stock · 400,000 shares Expires 2030-12-07 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on December 7, 2021. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 20:06 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantEmployee stock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001562180-19-001842 · primarydocument.xml · derivative · entry 1 Holcombe Stephen L. · CIK 0001648953 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,579 Underlying: Class A Common Stock · 200,000 shares Expires 2029-03-07 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on March 7, 2020. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 20:04 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantEmployee stock option (right to buy) · Derivative | 165,110 | $0.00 Strike: $5.81 | $0.00 |
DisclosureSEC source: 0001562180-17-001254 · primarydocument.xml · derivative · entry 1 Holcombe Stephen L. · CIK 0001648953 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,579 Underlying: Class A Common Stock · 165,110 shares Expires 2027-03-10 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on March 10, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.